Rexahn Pharmaceuticals, Inc. (RNN) Initiates Phase II Pancreatic Cancer Clinical Trial

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a leader in development of innovative therapeutics for life-threatening and life-debilitating diseases, announced today that it has received FDA approval to begin Phase II trials for Archexin?, the Company’s leading cancer compound, for the treatment of pancreatic cancer. This will be a multi-center trial with preliminary data in humans expected in 2010.

More: continued here

Filed under: Cancer on March 31st, 2009